Epithalon vs MK-677
A comprehensive, data-driven comparison of Epithalon (Epitalon) and MK-677 (Ibutamoren). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Epithalon Epitalon, Epithalone | MK-677 Ibutamoren, Nutrobal |
|---|---|---|
| FDA Status | Not submitted | Phase 2 |
| Category | Anti-Aging | Growth Hormone |
| Primary Use | Anti-aging and longevity research | Growth hormone optimization and muscle growth |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $40 - $80/mo | $50 - $100/mo |
| Administration | Subcutaneous injection | Oral |
| Typical Dose | 5-10mg per cycle (10-20 days, 2-3x per year) | 10-25mg daily |
| Frequency | Cyclical | Daily |
| Mechanism | Tetrapeptide that may activate telomerase enzyme to lengthen telomeres and potentially extend cellular lifespan | Oral growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | Emerging | Moderate |
| Clinical Trial Phase | N/A | Phase 2 |
Key Differences
- 1Epithalon is generally more affordable ($40 - $80/mo) compared to MK-677 ($50 - $100/mo).
- 2Epithalon is administered via subcutaneous injection, while MK-677 uses oral.
- 3Epithalon is dosed cyclical, while MK-677 is daily.
- 4MK-677 has moderate-quality evidence, while Epithalon has emerging-quality evidence.
- 5They belong to different categories: Epithalon (Anti-Aging) vs MK-677 (Growth Hormone).
Which Is Better For...
Epithalon
More budget-friendly option with lower monthly costs
Epithalon
More convenient dosing schedule (cyclical)
Epithalon
Fewer commonly reported side effects
MK-677
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Epithalon | $40 - $80/mo | Not submitted | Various research labs |
| MK-677 | $50 - $100/mo | Phase 2 | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Epithalon works via Tetrapeptide that may activate telomerase enzyme to lengthen telomeres and potentially extend. MK-677 works via Oral growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1. They differ in FDA approval status, efficacy data, and cost.
Epithalon typically costs $40 - $80/mo, while MK-677 costs $50 - $100/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Epithalon is not FDA-approved (Not submitted). MK-677 is not FDA-approved (Phase 2). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Epithalon include Injection site reactions, Mild drowsiness, Vivid dreams. Common side effects of MK-677 include Increased appetite, Water retention, Fatigue. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) researched primarily in Russia for its potential anti-aging properties. The proposed mechanism involves activation of telomerase, an enzyme that...
View Full Epithalon GuideMK-677 (Ibutamoren) is an orally-active growth hormone secretagogue that mimics the action of ghrelin. Unlike peptide injections, it is taken orally and has a long half-life allowing once-daily dosing...
View Full MK-677 GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Epithalon and MK-677 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.